|
1
|
Glass AG, Carreon JD, Lacey JV Jr and
Hoover RN: Breast cancer incidence, 1980–2006: combined roles of
menopausal hormone therapy, screening mammography, and estrogen
receptor status. J Natl Cancer Inst. 99:1152–1161. 2007.
|
|
2
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar
|
|
3
|
Ring A and Dowsett M: Mechanisms of
tamoxifen resistance. Endocr Relat Cancer. 11:643–658. 2004.
View Article : Google Scholar
|
|
4
|
Konecny G, Pauletti G, Pegram M, et al:
Quantitative association between HER-2/neu and steroid hormone
receptors in hormone receptor-positive primary breast cancer. J
Natl Cancer Inst. 95:142–153. 2003. View Article : Google Scholar
|
|
5
|
Slamon DJ, Godolphin W, Jones LA, et al:
Studies of the HER-2/neu proto-oncogene in human breast and ovarian
cancer. Science. 244:707–712. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nielsen TO, Hsu FD, Jensen K, et al:
Immunohistochemical and clinical characterization of the basal-like
subtype of invasive breast carcinoma. Clin Cancer Res.
10:5367–5374. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Peto R, Boreham J, Clarke M, Davies C and
Beral V: UK and USA breast cancer deaths down 25% in year 2000 at
ages 20–69 years. Lancet. 355:18222000.PubMed/NCBI
|
|
8
|
Boland GP, Butt IS, Prasad R, Knox WF and
Bundred NJ: COX-2 expression is associated with an aggressive
phenotype in ductal carcinoma in situ. Br J Cancer. 90:423–429.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Crawford YG, Gauthier ML, Joubel A, Mantei
K, Kozakiewicz K, Afshari CA and Tlsty TD: Histologically normal
human mammary epithelia with silenced p16(INK4a) overexpress COX-2,
promoting a premalignant program. Cancer Cell. 5:263–273. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Basu GD, Pathangey LB, Tinder TL, Lagioia
M, Gendler SJ and Mukherjee P: Cyclooxygenase-2 inhibitor induces
apoptosis in breast cancer cells in an in vivo model of spontaneous
metastatic breast cancer. Mol Cancer Res. 2:632–642.
2004.PubMed/NCBI
|
|
11
|
Kulp SK, Yang YT, Hung CC, et al:
3-phosphoinositide-dependent protein kinase-1/Akt signaling
represents a major cyclooxygenase-2-independent target for
celecoxib in prostate cancer cells. Cancer Res. 64:1444–1451. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Brasky TM, Bonner MR, Moysich KB, et al:
Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer
risk in the Western New York Exposures and Breast Cancer (WEB)
Study. Cancer Causes Control. 21:1503–1512. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Birt DF, Hendrich S and Wang W: Dietary
agents in cancer prevention: flavonoids and isoflavonoids.
Pharmacol Ther. 90:157–177. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lin Y, Shen HM, Shi R and Wang X:
Luteolin, a flavonoid with potential for cancer prevention and
therapy. Curr Cancer Drug Targets. 8:634–646. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Suh YJ, Chada S, McKenzie T, Liu Y,
Swisher SG, Lucci A and Hunt KK: Synergistic tumoricidal effect
between celecoxib and adenoviral-mediated delivery of mda-7 in
human breast cancer cells. Surgery. 138:422–430. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Basu GD, Liang WS, Stephan DA, Wegener LT,
Conley CR, Pockaj BA and Mukherjee P: A novel role for
cyclooxygenase-2 in regulating vascular channel formation by human
breast cancer cells. Breast Cancer Res. 8:R692006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chiang CT, Way TD and Lin JK: Sensitizing
HER2-overexpressing cancer cells to luteolin-induced apoptosis
through suppressing p21(WAF1/CIP1) expression with rapamycin. Mol
Cancer Ther. 6:2127–2138. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shih YL, Liu HC, Chen CS, et al:
Combination treatment with luteolin and quercetin enhances
antiproliferative effects in nicotine-treated MDA-MB-231 cells by
down-regulating nicotinic acetylcholine receptors. J Agric Food
Chem. 58:235–241. 2010. View Article : Google Scholar
|
|
19
|
Ghosh N, Chaki R, Mandal V and Mandal SC:
COX-2 as a target for cancer chemotherapy. Pharmacol Rep.
62:233–244. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sheng H, Shao J, Dixon DA, Williams CS,
Prescott SM, DuBois RN and Beauchamp RD: Transforming growth factor
beta1 enhances Ha-ras-induced expression of cyclooxygenase-2 in
intestinal epithelial cells via stabilization of mRNA. J Biol Chem.
275:6628–6635. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sheng H, Williams CS, Shao J, Liang P,
DuBois RN and Beauchamp RD: Induction of cyclooxygenase-2 by
activated Ha-ras oncogene in Rat-1 fibroblasts and the role of
mitogen-activated protein kinase pathway. J Biol Chem.
273:22120–22127. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sheng H, Shao J and Dubois RN:
K-Ras-mediated increase in cyclooxygenase 2 mRNA stability involves
activation of the protein kinase B1. Cancer Res. 61:2670–2675.
2001.PubMed/NCBI
|
|
23
|
Arico S, Pattingre S, Bauvy C, Gane P,
Barbat A, Codogno P and Ogier-Denis E: Celecoxib induces apoptosis
by inhibiting 3-phosphoinositide-dependent protein kinase-1
activity in the human colon cancer HT-29 cell line. J Biol Chem.
277:27613–27621. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Browning AM, Walle UK and Walle T:
Flavonoid glycosides inhibit oral cancer cell proliferation - role
of cellular uptake and hydrolysis to the aglycones. J Pharm
Pharmacol. 57:1037–1042. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ciolino HP, Wang TT and Yeh GC: Diosmin
and diosmetin are agonists of the aryl hydrocarbon receptor that
differentially affect cytochrome P450 1A1 activity. Cancer Res.
58:2754–2760. 1998.PubMed/NCBI
|
|
26
|
Doostdar H, Burke MD and Mayer RT:
Bioflavonoids: selective substrates and inhibitors for cytochrome
P450 CYP1A and CYP1B1. Toxicology. 144:31–38. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee LT, Huang YT, Hwang JJ, et al:
Blockade of the epidermal growth factor receptor tyrosine kinase
activity by quercetin and luteolin leads to growth inhibition and
apoptosis of pancreatic tumor cells. Anticancer Res. 22:1615–1627.
2002.PubMed/NCBI
|
|
28
|
Fang J, Zhou Q, Shi XL and Jiang BH:
Luteolin inhibits insulin-like growth factor 1 receptor signaling
in prostate cancer cells. Carcinogenesis. 28:713–723. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Solomon SD, McMurray JJ, Pfeffer MA, et
al: Cardiovascular risk associated with Celecoxib in a clinical
trial for Colorectal Adenoma Prevention. N Eng J Med.
352:1071–1080. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Horinaka M, Yoshida T, Shiraishi T, et al:
Luteolin induces apoptosis via death receptor 5 upregulation in
human malignant tumor cells. Oncogene. 24:7180–7189. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen D, Chen MS, Cui QC, Yang H and Dou
QP: Structure-proteasome-inhibitory activity relationships of
dietary flavonoids in human cancer cells. Front Biosci.
12:1935–1945. 2007. View
Article : Google Scholar : PubMed/NCBI
|
